Inhibition of fatty acid synthase activity in prostate cancer cells by dutasteride - PubMed (original) (raw)
. 2007 Jul 1;67(10):1111-20.
doi: 10.1002/pros.20602.
Affiliations
- PMID: 17477363
- DOI: 10.1002/pros.20602
Inhibition of fatty acid synthase activity in prostate cancer cells by dutasteride
Lucy J Schmidt et al. Prostate. 2007.
Abstract
Purpose: With malignant progression to androgen independence, prostate cancer cells develop resistance to apoptosis and exhibit a variety of gene expression changes, including increased fatty acid synthase (FASN) expression. Increased FASN expression has been shown to correlate with poor prognosis, and correspondingly, the FASN gene has been proposed as a therapeutic target. Because FASN is an androgen regulated gene in the prostate, we have examined the effects of dutasteride on FASN in prostate cancer cells in vitro. Dutasteride is a novel dual inhibitor of the 5 alpha-reductase enzymes and is currently in use both for treatment of benign prostate hyperplasia (BPH) and in the reduction by dutasteride of prostate cancer events (REDUCE) prostate cancer prevention trial.
Methods: Microarray analysis was used to identify genes affected by treatment with dutasteride, followed by real time PCR confirmation. FASN expression at the protein level was examined using Western blotting and immunocytochemistry. Enzymatic activity of FASN was assayed by (14)C-labeled malonyl-CoA incorporation. Viability after dutasteride treatment was assayed by MTS (Promega) and apoptosis via caspase 3/7 by DEVD cleavage assay.
Results: We have demonstrated that the 5 alpha-reductase inhibitor dutasteride, at clinically relevant levels, inhibits FASN mRNA, protein expression and enzymatic activity in prostate cancer cells.
Conclusions: This is the first study to examine the effects of clinically relevant levels of dutasteride on prostate cancer cells at the molecular level and specifically, demonstrating the inhibition of FASN in these cells.
Similar articles
- Effects of the dual 5 alpha-reductase inhibitor dutasteride on apoptosis in primary cultures of prostate cancer epithelial cells and cell lines.
Maria McCrohan A, Morrissey C, O'Keane C, Mulligan N, Watson C, Smith J, Fitzpatrick JM, Watson RW. Maria McCrohan A, et al. Cancer. 2006 Jun 15;106(12):2743-52. doi: 10.1002/cncr.21938. Cancer. 2006. PMID: 16703599 - Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT. Xu Y, et al. Clin Cancer Res. 2006 Jul 1;12(13):4072-9. doi: 10.1158/1078-0432.CCR-06-0184. Clin Cancer Res. 2006. PMID: 16818707 - Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Lazier CB, Thomas LN, Douglas RC, Vessey JP, Rittmaster RS. Lazier CB, et al. Prostate. 2004 Feb 1;58(2):130-44. doi: 10.1002/pros.10340. Prostate. 2004. PMID: 14716738 - Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer.
Thomas LN, Douglas RC, Lazier CB, Too CK, Rittmaster RS, Tindall DJ. Thomas LN, et al. Eur Urol. 2008 Feb;53(2):244-52. doi: 10.1016/j.eururo.2007.10.052. Epub 2007 Nov 5. Eur Urol. 2008. PMID: 18006217 Review. - Fatty acid synthase activity in tumor cells.
Little JL, Kridel SJ. Little JL, et al. Subcell Biochem. 2008;49:169-94. doi: 10.1007/978-1-4020-8831-5_7. Subcell Biochem. 2008. PMID: 18751912 Review.
Cited by
- RankAggreg, an R package for weighted rank aggregation.
Pihur V, Datta S, Datta S. Pihur V, et al. BMC Bioinformatics. 2009 Feb 19;10:62. doi: 10.1186/1471-2105-10-62. BMC Bioinformatics. 2009. PMID: 19228411 Free PMC article. - The role of protein post-translational modifications in prostate cancer.
Hao Y, Gu C, Luo W, Shen J, Xie F, Zhao Y, Song X, Han Z, He J. Hao Y, et al. PeerJ. 2024 Aug 12;12:e17768. doi: 10.7717/peerj.17768. eCollection 2024. PeerJ. 2024. PMID: 39148683 Free PMC article. Review. - Primary cilia are lost in preinvasive and invasive prostate cancer.
Hassounah NB, Nagle R, Saboda K, Roe DJ, Dalkin BL, McDermott KM. Hassounah NB, et al. PLoS One. 2013 Jul 2;8(7):e68521. doi: 10.1371/journal.pone.0068521. Print 2013. PLoS One. 2013. PMID: 23844214 Free PMC article. - Expression of X-linked inhibitor of apoptosis protein in human prostate cancer specimens with and without neo-adjuvant hormonal therapy.
Watanabe S, Miyata Y, Kanda S, Iwata T, Hayashi T, Kanetake H, Sakai H. Watanabe S, et al. J Cancer Res Clin Oncol. 2010 May;136(5):787-93. doi: 10.1007/s00432-009-0718-x. Epub 2009 Nov 28. J Cancer Res Clin Oncol. 2010. PMID: 19946707 - Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer.
Migita T, Ruiz S, Fornari A, Fiorentino M, Priolo C, Zadra G, Inazuka F, Grisanzio C, Palescandolo E, Shin E, Fiore C, Xie W, Kung AL, Febbo PG, Subramanian A, Mucci L, Ma J, Signoretti S, Stampfer M, Hahn WC, Finn S, Loda M. Migita T, et al. J Natl Cancer Inst. 2009 Apr 1;101(7):519-32. doi: 10.1093/jnci/djp030. Epub 2009 Mar 24. J Natl Cancer Inst. 2009. PMID: 19318631 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous